Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$190.66 -0.2%	$178.48	$140.68 ▼ $192.10	$460.19B	0.4	8.86 million shs	9.46 million shs
MS Morgan Stanley	$152.07 -2.7%	$151.61	$94.33 ▼ $163.98	$249.46B	1.32	5.55 million shs	5.52 million shs
MSFT Microsoft	$510.96 -2.2%	$513.12	$344.79 ▼ $555.45	$3.88T	1.03	19.85 million shs	24.03 million shs
PFE Pfizer	$24.81 -1.7%	$24.86	$20.92 ▼ $29.82	$143.50B	0.55	64.74 million shs	64.53 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.16%	+1.14%	+8.51%	+21.54%	+18.66%
MS Morgan Stanley	-2.65%	-3.39%	-1.36%	+6.90%	+39.46%
MSFT Microsoft	-2.19%	-1.24%	+2.12%	+1.52%	+22.40%
PFE Pfizer	-1.65%	-9.36%	+0.89%	-3.29%	-17.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$190.66 -0.2%	$178.48	$140.68 ▼ $192.10	$460.19B	0.4	8.86 million shs	9.46 million shs
MS Morgan Stanley	$152.07 -2.7%	$151.61	$94.33 ▼ $163.98	$249.46B	1.32	5.55 million shs	5.52 million shs
MSFT Microsoft	$510.96 -2.2%	$513.12	$344.79 ▼ $555.45	$3.88T	1.03	19.85 million shs	24.03 million shs
PFE Pfizer	$24.81 -1.7%	$24.86	$20.92 ▼ $29.82	$143.50B	0.55	64.74 million shs	64.53 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.16%	+1.14%	+8.51%	+21.54%	+18.66%
MS Morgan Stanley	-2.65%	-3.39%	-1.36%	+6.90%	+39.46%
MSFT Microsoft	-2.19%	-1.24%	+2.12%	+1.52%	+22.40%
PFE Pfizer	-1.65%	-9.36%	+0.89%	-3.29%	-17.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.73	Moderate Buy	$192.94	1.20% Upside
MS Morgan Stanley	2.59	Moderate Buy	$154.85	1.82% Upside
MSFT Microsoft	2.97	Moderate Buy	$618.47	21.04% Upside
PFE Pfizer	2.37	Hold	$28.35	14.30% Upside

Current Analyst Ratings Breakdown

Latest PFE, JNJ, MSFT, and MS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/10/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$209.00
10/10/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$33.00 ➝ $32.00
10/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$176.00 ➝ $178.00
10/9/2025	MSFT Microsoft	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/9/2025	JNJ Johnson & Johnson	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$186.00 ➝ $212.00
10/8/2025	JNJ Johnson & Johnson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2025	MS Morgan Stanley	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
10/8/2025	MSFT Microsoft	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
10/8/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
10/7/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $213.00
10/7/2025	MS Morgan Stanley	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$156.00 ➝ $165.00

(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$88.82B	5.17	$13.09 per share	14.56	$29.69 per share	6.42
MS Morgan Stanley	$107.29B	2.26	$11.21 per share	13.57	$59.39 per share	2.56
MSFT Microsoft	$281.72B	13.48	$17.89 per share	28.56	$46.21 per share	11.06
PFE Pfizer	$63.63B	2.22	$4.29 per share	5.78	$15.62 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$14.07B	$9.35	20.39	17.22	2.40	25.00%	32.49%	13.00%	10/14/2025 (Estimated)
MS Morgan Stanley	$13.39B	$8.83	17.22	16.13	1.82	13.06%	15.20%	1.15%	10/15/2025 (Estimated)
MSFT Microsoft	$101.83B	$13.64	37.46	34.76	2.27	36.15%	32.44%	18.20%	10/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.19	8.19	0.83	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest PFE, JNJ, MSFT, and MS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/29/2025	Q1 2026	MSFT Microsoft	$3.65	N/A	N/A	N/A	$75.49 billion	N/A
10/15/2025	Q3 2025	MS Morgan Stanley	$2.02	N/A	N/A	N/A	$16.42 billion	N/A
10/14/2025	Q3 2025	JNJ Johnson & Johnson	$2.78	N/A	N/A	N/A	$23.73 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/30/2025	Q4 2025	MSFT Microsoft	$3.35	$3.65	+$0.30	$3.65	$73.79 billion	$76.44 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion
7/16/2025	Q2 2025	MS Morgan Stanley	$1.98	$2.13	+$0.15	$2.13	$16.15 billion	$16.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	2.73%	N/A	55.61%	64 Years
MS Morgan Stanley	$4.00	2.63%	N/A	45.30%	12 Years
MSFT Microsoft	$3.32	0.65%	N/A	24.34%	23 Years
PFE Pfizer	$1.72	6.93%	N/A	91.49%	16 Years

Latest PFE, JNJ, MSFT, and MS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/15/2025	MSFT Microsoft	quarterly	$0.91	0.71%	11/20/2025	11/20/2025	12/11/2025
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
7/16/2025	MS Morgan Stanley	quarterly	$1.00	2.6%	7/31/2025	7/31/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.50	1.01	0.76
MS Morgan Stanley	3.30	0.78	0.78
MSFT Microsoft	0.12	1.35	1.35
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
MS Morgan Stanley	84.19%
MSFT Microsoft	71.13%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
MS Morgan Stanley	0.19%
MSFT Microsoft	0.03%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MS Morgan Stanley	80,000	1.60 billion	1.59 billion	Optionable
MSFT Microsoft	228,000	7.43 billion	7.43 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, JNJ, MSFT, and MS Headlines

Recent News About These Companies

Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation

1 hour ago | msn.com

Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.

October 10 at 8:18 PM | barrons.com

Pfizer (NYSE:PFE) Trading Down 1.7% - What's Next?

October 10 at 5:17 PM | marketbeat.com

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

October 10 at 3:51 PM | marketwatch.com

Sandoz granted tentative approval for generic of Pfizer's Inlyta

October 10 at 11:30 AM | seekingalpha.com

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

October 10 at 10:31 AM | finance.yahoo.com

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

October 10 at 10:15 AM | reuters.com

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)

October 10 at 10:05 AM | seekingalpha.com

JB Capital LLC Reduces Position in Pfizer Inc. $PFE

October 10 at 7:24 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Purchases 83,531 Shares of Pfizer Inc. $PFE

October 10 at 6:20 AM | marketbeat.com

Pfizer Inc. $PFE Holdings Boosted by Coerente Capital Management

October 10 at 5:40 AM | marketbeat.com

IFP Advisors Inc Raises Stake in Pfizer Inc. $PFE

October 10 at 5:31 AM | marketbeat.com

Blair William & Co. IL Reduces Stock Holdings in Pfizer Inc. $PFE

October 10 at 5:14 AM | marketbeat.com

Vontobel Holding Ltd. Purchases 14,808 Shares of Pfizer Inc. $PFE

October 10 at 4:51 AM | marketbeat.com

Maryland State Retirement & Pension System Buys 10,986 Shares of Pfizer Inc. $PFE

October 10 at 4:43 AM | marketbeat.com

First Merchants Corp Decreases Stock Holdings in Pfizer Inc. $PFE

October 10 at 4:42 AM | marketbeat.com

Stock Traders Buy High Volume of Call Options on Pfizer (NYSE:PFE)

October 10 at 2:12 AM | americanbankingnews.com

Pfizer (NYSE:PFE) Shares Down 1.8% - What's Next?

October 9 at 12:45 AM | marketbeat.com

Should You Buy Pfizer (PFE) Before a Breakout Begins?

October 9 at 11:31 PM | finance.yahoo.com

Here's Why Pfizer (PFE) Fell More Than Broader Market

October 9 at 6:46 PM | zacks.com

Pfizer Inc. (NYSE:PFE) Plans $0.43 Quarterly Dividend

October 9 at 5:37 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, JNJ, MSFT, and MS Company Descriptions

Johnson & Johnson NYSE:JNJ

$190.66 -0.43 (-0.22%)

Closing price 10/10/2025 03:59 PM Eastern

Extended Trading

$191.05 +0.40 (+0.21%)

As of 10/10/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Morgan Stanley NYSE:MS

$152.07 -4.20 (-2.69%)

Closing price 10/10/2025 03:59 PM Eastern

Extended Trading

$151.95 -0.12 (-0.08%)

As of 10/10/2025 07:58 PM Eastern

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.

Microsoft NASDAQ:MSFT

$510.96 -11.44 (-2.19%)

Closing price 10/10/2025 04:00 PM Eastern

Extended Trading

$511.96 +1.00 (+0.19%)

As of 10/10/2025 08:00 PM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

Pfizer NYSE:PFE

$24.80 -0.44 (-1.72%)

Closing price 10/10/2025 03:59 PM Eastern

Extended Trading

$24.65 -0.15 (-0.62%)

As of 10/10/2025 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, JNJ, MSFT, and MS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, JNJ, MSFT, and MS Earnings

Compare Dividends

Latest PFE, JNJ, MSFT, and MS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, JNJ, MSFT, and MS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, JNJ, MSFT, and MS Company Descriptions

Johnson & Johnson NYSE:JNJ

Morgan Stanley NYSE:MS

Microsoft NASDAQ:MSFT

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools